Roche leukaemia drug gets FDA breakthrough therapy designation
ZURICH: Roche Holding AG's Venclexta has won breakthrough therapy designation in acute myeloid leukaemia (AML) from the U.S. Food and Drug Administration, the Swiss drugmaker said on Friday.
The designation covers Venclexta in combination with low dose cytarabine for elderly patients with previously untreated AML who are ineligible for intensive chemotherapy, it said.
Venclexta is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Roche unit Genentech in the United States and by AbbVie elsewhere.
(Reporting by Michael Shields)
AbbVieacute myeloid leukaemiachemotherapycytarabineFDAleukaemialeukaemia drugRocheU.S. Food and Drug AdministrationVenclexta
Source : REUTERSNext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd